It has been proven as effective, if not more, than citalopram, as improvement rates for escitalopram are significantly higher than citalopram when the overall treatment effect was studied. Escitalopram has also been shown to be superior to the SNRI duloxetine, and also equivalent to, or better than venlafaxine. Due to the minimal side effects associated with escitalopram, long term remission rates have also been found to be higher than other antidepressants as well. Patients suffering from major depressive disorder exhibit favorable tolerance to escitalopram, regardless of short or long term therapy. Most side effects were mild and temporary, which included insomnia, nausea, excessive sweating, fatigue/somnolence, dysspermatism, and decreased libido. Escitalopram has significantly lower frequencies of adverse side effects than other SSRIs and SNRIs and discontinuation symptoms are also known to be more tolerable as well. (Kirino, 2012). In conclusion, Kirino (2012) notes “Because MDD recurs readily, it is important to select antidepressant drugs that allow high therapy continuity for pharmacological treatments. The effects of escitalopram highlighted in this review indicate that it is an antidepressant drug appropriate for first-line treatment.” Overall, escitalopram provides clients with better clinical outcomes and lower long-term mental health costs…